Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.36 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.36 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL476847 | 1.00 | SLC6A4 (0.37) | SLC6A4SLC6A2SLC6A3KCNH2SLC6A1 | |
| SCHEMBL1290220 | 1.00 | SLC6A4 (0.37) | SLC6A4SLC6A2SLC6A3KCNH2SLC6A1 | |
| SCHEMBL14632099 | 0.89 | SLC6A1 (0.43) | SLC6A4SLC6A2SLC6A3KCNH2SLC6A1 | |
| SCHEMBL124776 | 0.89 | SLC6A1 (0.43) | SLC6A4SLC6A2SLC6A3KCNH2SLC6A1 | |
| SCHEMBL612826 | 0.89 | SLC6A1 (0.43) | SLC6A4SLC6A2SLC6A3KCNH2SLC6A1 | |
| SCHEMBL13719286 | 0.89 | SLC6A1 (0.43) | SLC6A4SLC6A2SLC6A3KCNH2SLC6A1 | |
| SCHEMBL1305814 | 0.89 | GABRA5 (0.40) | SLC6A4SLC6A2SLC6A3SLC6A1GABRA5 | |
| SCHEMBL1564564 | 0.88 | SLC6A1 (0.38) | SLC6A4SLC6A2SLC6A3KCNH2SLC6A1 | |
| SCHEMBL16763685 | 0.88 | SLC6A1 (0.38) | SLC6A4SLC6A2SLC6A3KCNH2SLC6A1 | |
| SCHEMBL16763687 | 0.88 | SLC6A1 (0.38) | SLC6A4SLC6A2SLC6A3KCNH2SLC6A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| US-12325696-B2 | Indazole derivative, preparation method therefor, and pharmaceutical application thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2025-06-10 | — | — | US | disclosed |
| WO-2023109959-A1 | CDK9 INHIBITOR AND USE THEREOF | 药捷安康(南京)科技股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| CN-110105346-B | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-115557946-A | Heterocyclic lactam compound, pharmaceutical composition containing same and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-01-03 | — | — | CN | disclosed |
| WO-2022253309-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND APPLICATION THEREOF | 首药控股(北京)股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| US-20220267304-A1 | INDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-08-25 | — | — | US | disclosed |
| CN-114401955-A | Inhibitors of cyclin dependent kinases | 金耐特生物制药公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-109071560-B | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | 瓦洛健康公司 | 2022-01-14 | — | — | CN | disclosed |
| EP-3190116-B1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME | NIPPON SHINYAKU CO LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| US-7795256-B2 | Thieno-pyridinone derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2010-09-14 | — | — | US | disclosed |
| US-20100173901-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100069630-A1 | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-03-18 | — | — | US | disclosed |
| US-7655652-B2 | 2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidine hydrochloride; cell cycle inhibitory; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2010-02-02 | — | — | US | disclosed |
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | PALAU PHARMA, S.A. (ES) | 2009-12-10 | — | — | US | disclosed |
| US-20070161615-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| US-20070078131-A1 | Thieno-pyridinone derivatives as kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2007-04-05 | — | — | US | disclosed |
| US-7141596-B2 | Inhibitors of proteins that bind phosphorylated molecules | INCYTE CORPORATION (US) | 2006-11-28 | — | — | US | disclosed |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| US-20050272778-A1 | Inhibitors of proteins that bind phosphorylated molecules | INCYTE CORPORATION | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173901-A1 | Substituted Heterocyclic Compounds | HRH4, HRH2, HRH1 | SLC6A4 1012/4885SLC6A2 1020/4885SLC6A3 2506/4885 |
| US-20100069630-A1 | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC3, HDAC11 | SLC6A4 4254/4885SLC6A2 4559/4885SLC6A3 4493/4885 |
| US-20070161615-A1 | Chemical compounds | MKI67, PCNA, CCNI | SLC6A4 3268/4885SLC6A2 3165/4885SLC6A3 4044/4885 |
| US-12325696-B2 | Indazole derivative, preparation method therefor, and pharmaceutical application thereof | CYP19A1, HSD17B11, CYP51A1 | SLC6A4 2979/4885SLC6A2 4150/4885SLC6A3 3496/4885 |
| US-20050272778-A1 | Inhibitors of proteins that bind phosphorylated molecules | PPP3CA, PPP5C, PPM1A | SLC6A4 4520/4885SLC6A2 4688/4885SLC6A3 4453/4885 |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | SLC6A4 198/4885SLC6A2 179/4885SLC6A3 193/4885 |
| US-20220267304-A1 | INDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | CYP19A1, HSD17B11, CYP51A1 | SLC6A4 2979/4885SLC6A2 4150/4885SLC6A3 3496/4885 |
| US-20070078131-A1 | Thieno-pyridinone derivatives as kinase inhibitors | MAP3K6, MAP4K2, MAP3K15 | SLC6A4 3390/4885SLC6A2 3381/4885SLC6A3 3717/4885 |
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | HRH4, HRH2, HRH3 | SLC6A4 476/4885SLC6A2 558/4885SLC6A3 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.